Last reviewed: June 9, 2026
Last updated: June 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist used for weight loss and diabetes management, carries a pregnancy warning that requires careful patient education. The FDA classifies semaglutide in Category C for pregnancy, meaning animal studies raised concerns but human data remains limited. Anyone taking semaglutide who is pregnant, plans to become pregnant, or may become pregnant should discuss their situation with a healthcare provider immediately.
FDA Pregnancy Classification for Semaglutide and GLP-1 Drugs
The FDA places semaglutide in Pregnancy Category C, a designation indicating that animal reproduction studies have shown adverse fetal effects, but adequate human studies do not exist. This classification does not mean the drug causes birth defects in humans; rather, it reflects insufficient evidence to confirm safety. Because of this uncertainty, manufacturers and regulators recommend discontinuing semaglutide before attempting pregnancy or as soon as pregnancy is confirmed.
Other GLP-1 medications like tirzepatide carry similar pregnancy warnings. No large-scale randomized controlled trials have evaluated GLP-1 drugs in pregnant women, which is standard practice for medications in this class. PlexusDx advises all patients of reproductive age to use effective contraception while taking semaglutide injection or any GLP-1 therapy and to inform their healthcare team of family-planning goals.
What Animal Studies Revealed About Semaglutide in Pregnancy
Preclinical studies in rats and rabbits exposed to semaglutide doses higher than those used in humans showed delayed fetal development and organ maturation. These findings in animal models prompted caution but do not directly predict human outcomes. Importantly, animal studies often use doses many times higher than clinical doses, which may limit real-world relevance.
The data gap between animal and human evidence is why regulatory guidance emphasizes avoiding semaglutide during pregnancy. No birth defect pattern has been reported in humans exposed to semaglutide during pregnancy, but the number of documented exposures remains small. Healthcare providers typically balance the unknown risks of semaglutide against the known risks of untreated obesity during pregnancy when counseling patients.
Timing Your Weight Loss Treatment Before Conception
Patients planning pregnancy can benefit from starting semaglutide therapy several months before attempting to conceive. This timeline allows time to reach a therapeutic dose, stabilize weight loss, and then discontinue the medication safely before pregnancy. Stopping semaglutide typically requires no tapering—the drug clears the body within days to weeks—making transition planning straightforward with medical guidance.
Losing weight through semaglutide before pregnancy offers documented health benefits during gestation, including reduced gestational diabetes risk, lower blood pressure, and decreased cesarean delivery rates. Reaching a healthier weight before conception also improves fertility outcomes and pregnancy complications. PlexusDx recommends discussing timeline and contraception strategy with an obstetric provider while on semaglutide injection therapy.
Contraception Recommendations While Taking Semaglutide
Effective contraception is essential for anyone taking semaglutide who does not intend immediate pregnancy. Semaglutide does not reduce contraceptive effectiveness, meaning birth control pills, IUDs, implants, and barrier methods work as expected. However, gastrointestinal side effects like nausea or vomiting may theoretically reduce pill absorption, though this interaction is not formally documented.
Patients should discuss contraceptive options with their primary care or gynecology provider, as some methods may be preferable depending on individual health factors. Long-acting reversible contraception (LARC) methods such as intrauterine devices offer peace of mind for those taking semaglutide. PlexusDx encourages open communication between weight loss and obstetric providers to ensure coordinated, safe care.
What to Do If Pregnancy Occurs While on Semaglutide
If a patient discovers pregnancy while taking semaglutide injection, the medication should be discontinued immediately and an obstetrician contacted without delay. Early discontinuation reduces any potential fetal exposure and allows close prenatal monitoring. Do not abruptly stop semaglutide out of fear; instead, contact a healthcare provider right away for guidance specific to the pregnancy stage.
Pregnancy outcomes in women who took semaglutide before pregnancy or very early in pregnancy are not well documented. Most case reports in medical literature have not identified specific birth defects linked to early semaglutide exposure, but long-term follow-up data remains limited. An obstetrician can help assess individual risk, arrange appropriate prenatal testing if warranted, and provide reassurance based on current evidence.
Weight Management During and After Pregnancy
Weight management during pregnancy differs fundamentally from pre-pregnancy weight loss; intentional weight loss is not recommended during gestation. Instead, healthcare providers focus on preventing excessive weight gain and maintaining healthy nutrition and activity within medical guidelines specific to pregnancy. After delivery, semaglutide can be restarted if the patient is not breastfeeding, under medical supervision.
Breastfeeding mothers should not take semaglutide, as small amounts of the drug may pass into breast milk and effects on infants are unknown. Once breastfeeding ends, semaglutide therapy can resume at the lowest dose, with dose adjustment based on individual response. PlexusDx supports patients in resuming personalized weight loss therapy postpartum when it is medically appropriate.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is it safe to take semaglutide while pregnant?
No. Semaglutide is classified as FDA Pregnancy Category C and should not be used during pregnancy. Insufficient human safety data, combined with animal study findings, make discontinuation essential. Contact your healthcare provider immediately if you become pregnant while taking semaglutide.
Can I get pregnant while taking semaglutide injection?
Yes. Semaglutide does not affect fertility or contraceptive effectiveness. Anyone using semaglutide who could become pregnant should use reliable contraception and discuss family-planning timing with their provider before starting treatment.
How long should I stop semaglutide before trying to conceive?
Semaglutide clears the body within days to weeks of the final dose, so formal washout is not required. However, many providers recommend stopping 1-2 months before attempting pregnancy to ensure complete clearance. Discuss timing with your obstetric provider to coordinate your plan.
What if I took semaglutide early in pregnancy without knowing?
Contact your obstetrician immediately. Early discontinuation is the priority. While documented birth defect patterns from semaglutide exposure are limited, your provider can assess individual risk and arrange appropriate prenatal monitoring and testing as needed.
Can I take PlexusDx semaglutide starting at $149/month before pregnancy planning?
Yes. PlexusDx offers compounded semaglutide injection starting at $149/month from licensed 503A pharmacies, available in all 50 states without insurance. Patients planning pregnancy can use this therapy to reach a healthier weight months before conception, then discontinue safely when ready.
How does the Precision Peptide Genetic Test help with family planning?
PlexusDx Precision Peptide Genetic Test ($99 after first month) maps 14 pathways and 150+ genetic insights, including variants like GLP1R rs6923761 and MC4R rs17782313 that influence weight loss response. Understanding your peptide pathway before pregnancy allows optimized pre-conception weight management and personalized treatment if you resume therapy postpartum.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
The Role of GLP-1 Medications in Your Weight Loss Journey
What Foods Naturally Stimulate GLP-1 for Better Health?